Helix BioPharma Corp. (HBP.TO) TSX
Currency In CAD
- General
- Statistics
- Historical Data
- Profile
- Financials
Helix BioPharma Corp.
Address
9120 Leslie Street
Richmond Hill, ON L4B 3J9
Canada
Phone
905 841 2300
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
August 13, 1996
Key Executives
| Name | Title | Pay | Year Born |
| Thomas Mehrling | CEO & Chief Medical Officer | 318,920 | N/A |
| Jacek Antas | Chairman & Corporate Secretary | 100,000 | N/A |
| Davide Guggi | Chief Technology Officer | 213,599 | N/A |
| Veronika Kandziora | Chief Operating Officer | 232,241 | N/A |
| Rohit Babbar | Chief Financial Officer | 243,768 | N/A |
| Helen Middleton | General Counsel | 0 | N/A |
| Natalia L. Butterworth | Corporate Secretary | 0 | N/A |
| Jessica Kourniaktis DPHIL | Director of Communications | 0 | N/A |
Description
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has formed strategic alliances, including one with Moffitt Cancer Center to analyze L-DOS47's pharmacodynamics and assess the benefits of integrating it with immune checkpoint inhibitors. Another partnership, with ProMab Biotechnologies, Inc., is dedicated to creating innovative antibody and chimeric antigen receptor T-cell therapies to combat multiple myeloma. Furthermore, the company maintains licensing agreements with Xisle Pharma Ventures Trust and the National Research Council Canada.
